HealthDay Reporter
9 Wed, Jan. 7, 2022 (HealthDay News) — Patients suspected of having amyotrophic lateral sclerosis (ALS) may soon be diagnosed sooner rather than wasting a lot of money, new research suggests precious time left by people.
In 2020, scientists at Brain Chemistry Labs developed a microRNA (short fragment of genetic material)-based ALS Blood testing method, but it requires precise blood sample transportation and storage protocols, blood samples are kept at -80°C. This means that many doctors and neurologists cannot use the test.
Now, researchers from Dartmouth Neurology and the US Centers for Disease Control and Prevention report Said they have been able to replicate the original test using blood samples that were not collected and maintained under such strict requirements.
They participated by comparing 50 ALS patients with 50 healthy “controls” from the US National ALS Biorepository Blind blood samples from people to do this. The researchers found that in the new test, the genetic fingerprints of five microRNA sequences could accurately distinguish ALS patients from healthy individuals.
“We were surprised by the microRNA test Works with samples collected from a variety of researchers under different conditions,” said first author Dr. Sandra Banack. Doctors are now validating a new blood test, and a brain chemistry lab in Wyoming has applied for a patent for the test, according to a company press release.
ALS, also known as Lou Gehrig’s disease, is an incurable neurological disorder. Currently, the lag time between the onset of symptoms and the giving of a diagnosis is more than a year. An inaccurate diagnosis may occur in approximately 13% to 68% of cases. Unfortunately, most ALS patients die within two to five years of diagnosis. The findings were published online on August 29 in Journal of Neuroscience .More information The National Institute of Neurological Disorders and Stroke has more to learn about ALS. Source: Brain Chemistry Lab, Press Release, August 31, 2022
